Allergan aims to widen migraine treatment with MAP Pharma buy
(Reuters) – U. S. specialty drugmaker Allergan Inc said late on Tuesday that it would buy MAP Pharmaceuticals Inc for about $958 million in cash, an acquisition intended to widen its presence in the treatment of adult migraines. MAP Pharmaceuticals is developing Levadex, an orally inhaled drug for the acute treatment of migraines in adults. Levadex is currently under review by the U. S. Food and Drug Administration, which is set to make a decision about the drug around April 15. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply